NIKKEI 225
38,311.63 +237.65 (+0.62%) HANG SENG
18,803.61 +265.80 (+1.43%) CRUDE OIL
79.75 +0.49 (+0.62%) GOLD FUTURES
2,357.00 +16.70 (+0.71%) DOW
39,387.76 +331.36 (+0.85%) Bitcoin GBP
50,222.13 +1,054.89 (+2.15%)
MedinCell S.A. (MEB.F)
| Previous close | 14.60 |
| Open | 15.92 |
| Bid | 15.26 x 0 |
| Ask | 15.56 x 0 |
| Day's range | 15.92 - 15.92 |
| 52-week range | 5.51 - 15.92 |
| Volume | |
| Avg. volume | 18 |
| Market cap | 470.132M |
| Beta (5Y monthly) | 1.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.01 |
| Earnings date | 25 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
PARSIPPANY, N.J. & TEL AVIV & PARIS, May 08, 2024--ACCESS HERE THE COMPLETE PRESS RELEASE
- Business Wire
Medincell announces the suspension of listing of its shares on Euronext Paris
MONTPELLIER, France, May 08, 2024--Regulatory News: The listing of the Medincell (Paris:MEDCL) shares on Euronext Paris has been suspended at the request of the Company, pending the publication of a press release. Trading on Euronext Paris will resume tomorrow at the opening of markets.
Business WireMedincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies
MONTPELLIER, France, April 16, 2024--Regulatory News: Medincell (Paris:MEDCL) today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will use its commercial-stage long-acting injectable technology platform to formulate innovative therapies. Medincell will conduct formulation activities and preclinical studies, including supportive CMC work to advance candidates into clinical trials. A
